antibody
-
DrugTimes BD Project DTC-059 | Dual-Action FXl/FXla Inhibitor: A Low-Bleeding，Superior-Efficacy Antibody with Best-in-Class Potential
While numerous anticoagulants with diverse mechanisms of action (e.g., Eliquis, heparin, w…
-
Seeking Partners for a Bispecific Antibody Targeting IL4Rα/IL13 and IL31 for Atopic Dermatitis | DrugTimes BD Project
In the early clinical development of atopic dermatitis (AD), multiple inflammatory factors…
-
Disruptive change? How should we really view the new FDA policies?
For more reports, please follow DrugTimes. Many thanks!
